Search research articles
Contact Us
Filters
Showing results (11-20 of 77) with videos related to
Page
of 8
Sort By:
Current Drug Targets
|
April 2, 2016
Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Rosalinda Madonna, Christian Cadeddu, Martino Deidda, et al.
British Journal of Clinical Pharmacology
|
February 23, 2021
Cardiovascular safety of the tyrosine kinase inhibitor nintedanib
Pietro Ameri, Giacomo Tini, Paolo Spallarossa, et al.
Pediatric Blood & Cancer
|
September 22, 2023
Reply to Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane
Nicoletta Bertorello, Roberto Luksch, Gianni Bisogno, et al.
Journal of Thrombosis and Thrombolysis
|
August 29, 2025
Practical considerations about management of pulmonary embolism in patients with cancer
Lorenzo Bianchi, Giorgio Ghigliotti, Matteo Sarocchi, et al.
Frontiers in Pharmacology
|
July 18, 2020
How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
Paolo Spallarossa, Matteo Sarocchi, Giacomo Tini, et al.
Pediatric Blood & Cancer
|
June 25, 2023
Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane
Nicoletta Bertorello, Roberto Luksch, Gianni Bisogno, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 21, 2009
Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane
Paolo Spallarossa, Paola Altieri, Paolo Pronzato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2019
Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely
Paolo Spallarossa, Giacomo Tini, Matteo Sarocchi, et al.
Plos One
|
October 11, 2012
Inhibition of doxorubicin-induced senescence by PPARδ activation agonists in cardiac muscle cells: cooperation between PPARδ and Bcl6
Paola Altieri, Paolo Spallarossa, Chiara Barisione, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|
November 9, 2022
Does the HFA/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?
Giacomo Tini, Matteo Sarocchi, Pietro Ameri, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 77) with videos related to
Sort By:
Page
of 8
Current Drug Targets
|
April 2, 2016
Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Rosalinda Madonna, Christian Cadeddu, Martino Deidda, et al.
British Journal of Clinical Pharmacology
|
February 23, 2021
Cardiovascular safety of the tyrosine kinase inhibitor nintedanib
Pietro Ameri, Giacomo Tini, Paolo Spallarossa, et al.
Pediatric Blood & Cancer
|
September 22, 2023
Reply to Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane
Nicoletta Bertorello, Roberto Luksch, Gianni Bisogno, et al.
Journal of Thrombosis and Thrombolysis
|
August 29, 2025
Practical considerations about management of pulmonary embolism in patients with cancer
Lorenzo Bianchi, Giorgio Ghigliotti, Matteo Sarocchi, et al.
Frontiers in Pharmacology
|
July 18, 2020
How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
Paolo Spallarossa, Matteo Sarocchi, Giacomo Tini, et al.
Pediatric Blood & Cancer
|
June 25, 2023
Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane
Nicoletta Bertorello, Roberto Luksch, Gianni Bisogno, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 21, 2009
Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane
Paolo Spallarossa, Paola Altieri, Paolo Pronzato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2019
Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely
Paolo Spallarossa, Giacomo Tini, Matteo Sarocchi, et al.
Plos One
|
October 11, 2012
Inhibition of doxorubicin-induced senescence by PPARδ activation agonists in cardiac muscle cells: cooperation between PPARδ and Bcl6
Paola Altieri, Paolo Spallarossa, Chiara Barisione, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|
November 9, 2022
Does the HFA/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?
Giacomo Tini, Matteo Sarocchi, Pietro Ameri, et al.
Page
of 8